ERBB2 and breast carcinoma: These authors observed that miR-489 was underexpressed in this type of cancer, especially through the MAPK pathway, In a later in vitro experiment in xenograft mice, they determined that overexpression of this microRNA in HER2-positive breast cancer cells significantly inhibited cell growth and decreased tumorigenicity and tumor growth.